RT Journal Article SR Electronic T1 CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody–associated Vasculitis: 2020 Update JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.200721 DO 10.3899/jrheum.200721 A1 Arielle Mendel A1 Daniel Ennis A1 Ellen Go A1 Volodko Bakowsky A1 Corisande Baldwin A1 Susanne M. Benseler A1 David A. Cabral A1 Simon Carette A1 Marie Clements-Baker A1 Alison H. Clifford A1 Jan Willem Cohen Tervaert A1 Gerard Cox A1 Natasha Dehghan A1 Christine Dipchand A1 Navjot Dhindsa A1 Leilani Famorca A1 Aurore Fifi-Mah A1 Stephanie Garner A1 Louis-Philippe Girard A1 Clode Lessard A1 Patrick Liang A1 Damien Noone A1 Jean-Paul Makhzoum A1 Nataliya Milman A1 Christian A. Pineau A1 Heather N. Reich A1 Maxime Rhéaume A1 David B. Robinson A1 Dax G. Rumsey A1 Tanveer E. Towheed A1 Judith Trudeau A1 Marinka Twilt A1 Elaine Yacyshyn A1 Rae Yeung A1 Lillian Barra A1 Nader Khalidi A1 Christian Pagnoux YR 2020 UL http://www.jrheum.org/content/early/2021/01/25/jrheum.200721.abstract AB Objective In 2015, the Canadian Vasculitis Research Network (CanVasc) created recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada. The current update aims to revise existing recommendations and create additional recommendations, as needed, based on a review of new available evidence. Methods A needs assessment survey of CanVasc members informed questions for an updated systematic literature review (publications spanning May 2014 to September 2019) using Medline, Embase, and Cochrane. New and revised recommendations were developed and categorized according to the level of evidence and strength of each recommendation. The CanVasc working group used a 2-step modified Delphi procedure to reach > 80% consensus on the inclusion, wording, and grading of each new and revised recommendation. Results Eleven new and 16 revised recommendations were created and 12 original (2015) recommendations were retained. New and revised recommendations are discussed in detail within this document. Five original recommendations were removed, of which 4 were incorporated into the explanatory text. The supplementary material for practical use was revised to reflect the updated recommendations. Conclusion The 2020 updated recommendations provide rheumatologists, nephrologists, and other specialists caring for patients with AAV in Canada with new management guidance, based on current evidence and consensus from Canadian experts.